Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EN3356 is an orally available and selective inhibitor of steroidal 17-alpha-hydroxylase/C17,20 cleavage enzyme (CYP17A1 or CYP17), a non-steroidal cleavage enzyme-selective compound with potential anti-androgenic and anti-tumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 90.00 | |
5 mg | In stock | $ 210.00 | |
10 mg | In stock | $ 310.00 | |
25 mg | In stock | $ 586.00 | |
50 mg | In stock | $ 790.00 | |
100 mg | In stock | $ 1,080.00 | |
500 mg | In stock | $ 2,190.00 |
Description | EN3356 is an orally available and selective inhibitor of steroidal 17-alpha-hydroxylase/C17,20 cleavage enzyme (CYP17A1 or CYP17), a non-steroidal cleavage enzyme-selective compound with potential anti-androgenic and anti-tumor activity. |
In vivo | EN3356 (50, 100, 200 mg; oral; escalating doses; once a day) was well tolerated, and drug-related AEs were CTCAE Gr 1 and 2 incl. myalgia, anorexia, flushing, hot flashes, and presyncope. Excellent systemic exposure was observed at both 50 mg and 100 mg QD regimens (Cmax, Ctrough, and AUCτ at 100 mg QD were 3.5 uM, 1.8 uM, and 52 uM.h, respectively). The Phase 1 clinical study results to date show that EN3356 is safe and well tolerated at doses of up to 100 mg daily.[1] |
Synonyms | AS N001, ASN-001 |
Molecular Weight | 300.35 |
Formula | C16H13FN2OS |
CAS No. | 1429329-63-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 7.5 mg/mL (24.97 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EN3356 1429329-63-4 Metabolism P450 AS N001 ASN 001 EN-3356 AS N-001 ASN-001 AS N 001 EN 3356 ASN001 inhibitor inhibit